A business model where capital hardware (the 'razor') is placed at low margin or via no-capital programs to drive recurring sales of consumables, instruments, or single-use components (the 'razor blade'). Surgical robotics, EP mapping, blood-glucose monitoring, and IVD instruments classically follow this model. The company sells or places the device at low margin and earns recurring revenue on consumables or disposables. It is common in diagnostics, robotics and some surgical tools. Antitrust and contract terms must be managed so tying arrangements are lawful.

Why it matters

Pull-through per installed system is the operating metric that matters. CapEx-strapped buyers favor reagent-rental and managed-service variants.

Common pitfalls

•Manufacturers might face scrutiny if the "blade" component is designed to be proprietary in a way that creates an undue barrier to competition or compromises patient safety with alternative "blades."
•Failure to adequately test and validate the "razor" and "blade" components together can lead to regulatory non-compliance and adverse events.
•Changing a "blade" component, even a seemingly minor one, without proper regulatory submission and impact analysis can be considered an unauthorized modification to the MedTech system.
•The supply chain for both "razor" and "blade" components must be robust and controlled, as stockouts could lead to patient care disruptions and regulatory issues.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.